Daxor (DXR) vs LENSAR (LNSR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Daxor (DXR) has outperformed LENSAR (LNSR) over the past year, losing 18.2% versus a loss of 46.9%. Over five years, DXR leads with a -7.5% price change compared with -15.3% for LNSR. LENSAR is the larger company by market cap ($78.3 million vs $60.8 million), about 1.3 times the size.
On valuation, Daxor trades at a lower trailing P/E (9.5x vs 35.4x for LENSAR).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | LNSR |
|---|---|---|
| Share price | $10.41 | $6.37 |
| Market cap | $60.78M | $78.26M |
| 1-day change | -0.48% | -1.24% |
| YTD return | -29.42% | -45.23% |
| 1-year return | -18.22% | -46.87% |
| 5-year return | -7.47% | -15.29% |
| P/E ratio (TTM) | 9.46 | 35.39 |
| EPS (TTM) | $1.10 | $0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $12.94 |
| 52-week low | $8.56 | $4.95 |
| Distance from 52-week high | -29.47% | -50.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.12% | +77.86% |
| Average volume | 17.38K | 102.05K |
| Shares outstanding | 5.84M | 12.29M |
| Employees | — | 150 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed LNSR by 28.6 percentage points over the past year.
- LENSAR trades at a higher earnings multiple (35.4x vs 9.5x trailing P/E).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
DXR vs LNSR FAQ
Which is bigger, Daxor or LENSAR?
LENSAR (LNSR) is larger, with a market capitalization of $78.26M compared with $60.78M for Daxor (DXR).
Which stock has performed better over the past year, DXR or LNSR?
DXR returned -18.22% over the past 12 months, compared with -46.87% for LNSR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXR or LNSR?
DXR has the lower trailing P/E at 9.5, versus 35.4 for LNSR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Daxor and LENSAR in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.